In yesterday’s Wall Street session, Roivant Sciences Ltd (NASDAQ:ROIV) shares traded at $9.09, up 2.25% from the previous session.
10 analysts cover Roivant Sciences Ltd (NASDAQ:ROIV), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $12.00, we find $16.00. Given the previous closing price of $8.89, this indicates a potential upside of 79.98 percent. ROIV stock price is now -13.27% away from the 50-day moving average and -4.79% away from the 200-day moving average. The market capitalization of the company currently stands at $7.19B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 9. Brokers who have rated the stock have averaged $16.44 as their price target over the next twelve months.
With the price target of $17, Guggenheim recently initiated with Buy rating for Roivant Sciences Ltd (NASDAQ: ROIV).
In other news, Venker Eric, Chief Operating Officer sold 153,027 shares of the company’s stock on Oct 05. The stock was sold for $1,547,103 at an average price of $10.11. Upon completion of the transaction, the Chief Operating Officer now directly owns 595,397 shares in the company, valued at $5.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 03, Chief Operating Officer Venker Eric sold 606,221 shares of the business’s stock. A total of $6,213,765 was realized by selling the stock at an average price of $10.25. This leaves the insider owning 595,397 shares of the company worth $5.41 million. A total of 32.50% of the company’s stock is owned by insiders.
On Tuesday morning Roivant Sciences Ltd (NASDAQ: ROIV) stock kicked off with the opening price of $8.94. During the past 12 months, Roivant Sciences Ltd has had a low of $4.71 and a high of $13.24. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 6.37, and a quick ratio of 6.35. The fifty day moving average price for ROIV is $10.48 and a two-hundred day moving average price translates $9.55 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.3 by -0.08. This compares to -$0.51 EPS in the same period last year. The net profit margin was -1233.11% and return on equity was -94.44% for ROIV. The company reported revenue of $21.62 million for the quarter, compared to $4.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 400.67 percent. For the current quarter, analysts expect ROIV to generate $30.12M in revenue.
Roivant Sciences Ltd(ROIV) Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn’s disease. The company was founded in 2014 and is based in London, the United Kingdom.
